Scrip Podcasts

In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年11月6日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：马德里加尔公司（Madrigal）的MASH项目举报人；礼来（Lilly）将继续推进并购；赛诺菲（Sanofi）正在寻求后期研发资产；辉瑞（Pfizer）上调业绩预期；以及LIB公司PCSK9药物的定价。 Story links here. 向听众们简要更新一下：Scrip 现在已在 Spotify&nbsp...

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Nov. 6, 2026. This time—Madrigal’s MASH whistleblower; Lilly’s dealmaking to continue; Sanofi hunting late-stage assets; Pfizer raises guidance; and...

"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen Biosciences, and Roche paid more than $1 billion for an RNAi obesity drug from Rona Therapeutics. Meanwhile, Merck and Moderna’s personalized melanoma vaccine cut the risk of recurrence or death by 42% in a Phase 3 trial. So,...

For emerging biotech companies, development success is often measured by clinical milestones, safety, and efficacy. However, demonstrating an asset’s value extends beyond regulatory approval. Understanding patient needs and treatment experiences, as well as evolving stakeholder expectations, early in development plays an important role in shaping a more informed evidence strategy. In this podcast,...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月30日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：美国《COINS法案》的影响；葛兰素史克（GSK）在肿瘤领域的业务转型；礼来（Lilly）在KRAS领域的推进；ris-rez为骨肉瘤治疗带来新希望；以及Genmab最新III期临床试验的胜利。 Story links here. 向听众们简要更新一下：Scrip 现在已在 Spotify 和&n...

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 30, 2026. This time—US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s late...

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 23, 2026. This time—key expectations from ESMO meeting; next-generation antibody-drug conjugates; rising mid-cap stars; GSK's novel hepatitis B...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月23日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：欧洲肿瘤内科学会（ESMO）会议的关键预期；新一代抗体药物偶联物；冉冉升起的中盘股新星；葛兰素史克（GSK）新型乙肝药物的上市；以及私营企业的重大融资动态。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/sc...

Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：Tremfya从Stelara的余烬中崛起；辉瑞将成熟品牌作为试验田；中国科研力量在第三季度交易中大放异彩；Argenx在自身免疫领域取得进展与遭遇挫折；日本力图重振生物制药竞争力。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-k...

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 16, 2026. This time—Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune wi...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美元的收购案。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know...

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 9, 2026. This time—China’s competitive threat; M&As cool off in Q3; new pneumococcal vaccine contender; strategy for Spanish biotechs; and Shionogi’s...

Despite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult. As biomarkers, AI and precision medicine become increasingly integrated into clinical research, sponsors have new opportunities to strengthen study design, improve patient...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月2日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 谁在引领今年的并购步伐；罗氏（Roche）的研发管线重整；湿性黄斑变性（wet AMD）市场的洗牌；默克公司（Merck & Co.）撤回I-DXd申报；以及默克将Recarbio从市场上撤回。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/qui...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Oct. 2, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—who’s setting the M&A pace this year; Roche’s pipeline reset; wet AMD market shakeup; Merck & Co. pulls I-DXd filing; and Merck withdraws Recarbio from the market.  Story links: https://insig...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月25日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 中国带来的变革效应；诺和诺德的新战略；罗氏的抗肥胖新药；安进在舍格伦综合征治疗领域的胜利；以及中国潜在的重磅药物。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WVD7A...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 25, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—China’s transforming effect; Novo’s new strategy; Roche’s obesity contender; Amgen’s Sjögren’s win; and potential Chinese blockbusters.  Story links: https://insights.citeline.com/scrip/pod...

Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-perfo...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 本期内容包括：近期III期试验失败后，心血管领域研发的下一步动向；全球销量前十的药物中有九款在第二季度实现连续增长；阿斯利康的首创性慢性阻塞性肺病（COPD）药物在III期试验中表现优于Dupixent；Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成功；...

根据Citeline旗下Scrip在2026年9月4日发布的最新统计，截至今年8月底，已经有六个由中国药企作为唯一申办方且在美国招募患者的全球III期临床试验启动。这个节奏已经追平了2025年全年的总量。今天我们就把这六个临床试验挨个拆开来看，再聊聊这背后代表的行业信号。 Story link: https://insights.citeline.com/scrip/r-and-d/clinical-trials/chinese-firms-start-six-global-phase-iii-trials-with-us-sites-so-far-in-2026-...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月28日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来研究显示Zepbound带来的成本节约可能超过其售价；罗氏达成最高23亿美元的韩美制药“肌肉保护型”减肥药交易；Revolution的Rasonque获美国批准用于治疗胰腺癌，Jazz的Ziihera获批用于治疗胃食管癌；以及梯瓦和维亚特里斯从仿制药转向创新药。 Story link: https://ins...